Sign In
Buy EVOK
$10.69
+0 (+0%)
At Close: Nov 17, 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Evoke Pharma, Inc. (NASDAQ: EVOK)
06:00pm, Tuesday, 04'th Nov 2025
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders
11:28am, Tuesday, 04'th Nov 2025
MILWAUKEE , Nov. 4, 2025 /PRNewswire/ -- The Ademi Firm is investigating Evoke (NASDAQ: EVOK) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction
EVOK Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Evoke Pharma, Inc. is Fair to Shareholders
10:07am, Tuesday, 04'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Evoke Pharma, Inc. (NASDAQ: EVOK) to QOL Medical, LLC for $11.00 per share in cash is fai
CLEVELAND--(BUSINESS WIRE)--Partnership creates national RIA with 600 employees and $65 billion in AUM.
William Hill owner Evoke threatens betting shop closures if taxes go up
04:16am, Monday, 13'th Oct 2025
William Hill owner Evoke PLC (LSE:EVOK) has joined Ladbrokes owner Entain PLC (LSE:ENT) in threatening to close hundreds of betting shops if November's Budget brings new taxes on the industry.
Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year
09:08am, Friday, 03'rd Oct 2025
LOS ANGELES--(BUSINESS WIRE)--Ranking recognizes Evoke's achievement in advancing client experience, and its leadership as a trusted advisor in the RIA industry.
MAI Capital Management Announces Strategic Partnership with Evoke Advisors
09:30am, Wednesday, 27'th Aug 2025
CLEVELAND & LOS ANGELES--(BUSINESS WIRE)--MAI Capital Management strategically partners with Evoke Advisors. Together, the firm will manage approximately $60 billion across over 30 offices.
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship
07:00am, Tuesday, 26'th Aug 2025
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
07:00am, Thursday, 21'st Aug 2025
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038
06:30am, Wednesday, 06'th Aug 2025
Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection Extends market exclusivity for GIMOTI® to November 2038, nearly two additional ye
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
08:16am, Wednesday, 09'th Jul 2025
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
04:05pm, Tuesday, 13'th May 2025
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIR
SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasi
evoke makes a steady exit from the Q1 starting gate
02:42am, Friday, 25'th Apr 2025
Evoke PLC (LSE:EVOK) has kicked off 2025 with a steady start, reporting first-quarter revenue of £437.00 million—up 1% on last year and pretty much bang on with what it had guided. So far this yea
William Hill owner Evoke falls at the first-quarter update
05:01am, Wednesday, 26'th Mar 2025
Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025. Results for the past calen
